Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Reports Increased Revenue, Contracted R&D in Q4

NEW YORK, Feb. 6 - Caliper Technologies on Wednesday reported widened net losses for the fourth quarter 2001 despite a 58 percent increase in revenue and a contraction in R&D spending.

 

Total revenue for the period ended Dec. 31 was $7.9 million compared with $5 million in the year-ago quarter, Caliper said in a statement. The increase was fueled largely by a $2.8 million surge in sales of its high-throughput instruments and its LabChip kits that pulled product revenue to $4 million in the quarter.

 

R&D spending fell to $9.9 million from $10.8 million one year ago. Despite this the company posted a net loss for the period of $8 million, or $.33 per share, compared with $5.8 million, or $.25, year over year.

 

Caliper said it had roughly $166 million in the bank as of Dec. 31.

 

Furthermore, the company said, "As anticipated, Caliper's conversion to a commercial products business from a fee-based business model resulted in Technology Access Program revenue [in the current fourth quarter] declines of 50 percent" over the same period last year.

According to Jim Knighton, Caliper's executive vice president and CFO, the company is "entering 2002 well-positioned for further revenue growth and, while we expect expenses (including cost of goods) to increase, we expect them to do so at a significantly lesser rate than revenues."

 

In December last year, Caliper signed a deal with Bacterial BarCodes  to develop and co-distribute a clinical diagnostic system to detect and diagnose invasive bacterial infections.

 

It was the first commercial diagnostics deal for Mountain View, Calif.-based Caliper, the company said.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.